Quick View
| Metric | Current Period | Same Period of Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥28.9B | ¥31.7B | −8.7% |
| Operating Income | −¥2.7B | −¥7.1B | +61.3% |
| Profit Before Tax | ¥3.7B | −¥3.0B | +223.9% |
| Net Income | ¥1.9B | −¥4.7B | +140.7% |
| ROE | 0.5% | −1.2% | - |
Executive Summary
The results were characterized by improved profitability despite declining revenue. Although the operating loss narrowed, the increase in net income depended on non-operating factors such as financial income. Revenue continued to decline, at ¥28.9B (¥31.7B in the previous year, -8.7% YoY). Operating income was ¥-2.7B, representing a 61.3% reduction in the loss from ¥-7.1B in the previous year. Net income turned positive at ¥1.9B (¥-4.7B in the previous year); however, the result was heavily supported by financial income of ¥7.9B and other income of ¥4.3B, and therefore does not indicate the earning power of the core business.
Factors Affecting Earnings
【Revenue】Revenue was ¥28.9B, a decrease of 8.7% YoY. Although segment information was not disclosed, the gross margin remained high at 61.4% (up YoY), suggesting that deterioration in pricing and product mix was limited. Meanwhile, the contraction in revenue itself is weakening the company’s ability to absorb fixed costs.
【Profitability】Operating income was ¥-2.7B, representing a 61.3% reduction in the loss from ¥-7.1B in the previous year. The improvement was attributable to a decline in cost of sales to ¥11.2B (¥15.3B in the previous year), which improved the gross margin, as well as a reduction in SG&A expenses to ¥24.3B (¥26.8B in the previous year). Profit Before Tax was ¥3.7B, improving to a level substantially above the operating loss due to non-operating factors including financial income of ¥7.9B and other income of ¥4.3B. Net income was ¥1.9B, reflecting an increase in profit despite declining revenue, driven by improved core operating results and dependence on non-operating income.
Key Financial Indicators
【Profitability】The operating margin was -9.5% (improving from approximately -22.3% in the previous year), while the SG&A ratio reached 84.0% against a gross margin of 61.4%, indicating that the fixed-cost burden is weighing on operating profitability. The net margin was 6.6%; however, it is highly dependent on financial income and other income and does not reflect the earning power of the core business. 【Cash Flow Quality】Operating Cash Flow (OCF) was ¥3.0B, approximately 1.6 times net income of ¥1.9B, indicating that the current period’s earnings had adequate cash backing. 【Investment Efficiency】ROE was 0.5%, and the total asset turnover ratio was low at 0.059x, with the limited ability to generate revenue relative to the asset base being the primary cause of the low ROE. 【Financial Soundness】The equity ratio was 81.2% (81.5% in the previous year), and the debt-to-equity ratio was 0.23x, indicating that the company maintains low financial leverage and a conservative capital structure.
Cash Flow Analysis
Operating Cash Flow was ¥3.0B, a significant increase from ¥0.5B in the previous year, providing cash backing for net income; however, the absolute amount remains limited given the operating loss. Investing Cash Flow was an inflow of ¥21.5B, primarily because proceeds of ¥179.8B from the sale of investment securities exceeded the expenditures for their acquisition, while capital expenditures remained limited at ¥0.1B. Financing Cash Flow was ¥-1.5B, mainly due to lease payments and other items. Free cash flow was substantial at ¥24.5B, but the majority resulted from the temporary factor of selling the investment portfolio and was not generated solely through operating activities and capital expenditures. Cash and cash equivalents accumulated to ¥92.0B, providing a certain degree of flexibility in the financial base.
Quality of Earnings
Profit Before Tax of ¥3.7B for the current period was formed by adding financial income of ¥7.9B and other income of ¥4.3B—non-operating and non-recurring factors—to the operating loss of ¥-2.7B, and therefore does not represent recurring business earning power. The effective tax rate was high at 48.6%, and the tax burden coefficient was 0.516, meaning that nearly half of Profit Before Tax was reduced by corporate income taxes and other tax-related expenses. Operating Cash Flow was ¥3.0B, exceeding net income of ¥1.9B. From an accruals perspective, the divergence between earnings and cash flow was small, and there is no apparent issue with the cash backing of current-period earnings itself. However, the majority of Investing Cash Flow resulted from the non-recurring sale of investment securities; excluding this factor, the company’s underlying cash-generating capacity remains limited.
Shareholder Returns
The Q2 dividend was ¥0, and the company continues to pay no dividends. As no dividend was paid, the payout ratio was 0%. Given that operating income remains negative and OCF is also limited, the current policy appears to prioritize the allocation of funds to research and development and the business foundation over dividends.
Risk Factors
-
Low operating earning power: The operating margin was -9.5%, significantly below the industry median of 8.6%. Research and development expenses accounted for 23.3% of revenue, creating a risk that the fixed-cost burden will persist over the long term if commercialization does not progress.
-
Declining inventory efficiency: Inventories were ¥10.4B, and annualized DIO was extended at 256 days. The possibility of valuation losses associated with fluctuations in demand and technological obsolescence should be monitored.
-
Dependence on non-recurring cash flow: The ¥21.5B inflow from Investing Cash Flow resulted from the sale of investment securities and must be evaluated separately from the company’s cash-generating capacity through operating activities alone.
Industry Benchmark (For Reference; Compiled by the Company)
Key Points from the Financial Results
-
The operating loss narrowed by 61.3% from the previous year, with the maintenance of a 61.4% gross margin and reductions in SG&A expenses contributing to the improvement. Profitability improved despite an 8.7% decline in revenue, suggesting that the company may be making progress in reviewing its cost structure.
-
The turnaround to positive net income was highly dependent on financial income and other income, while operating income remains negative. This is an important consideration when evaluating the sustainable earning power of the business.
-
The conservative financial base, including an equity ratio of 81.2% and cash and cash equivalents of ¥92.0B, provides capacity to support research and development investment and progress in business adoption.
This report is an earnings analysis document automatically generated by AI based on XBRL financial results data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the company based on publicly available financial results data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
CYBERDYNE's FY2026 Q3 result shows a meaningful year-on-year narrowing of the operating loss and a return to net profitability, but the improvement was driven by non-operating income rather than a recovery in the core business. Revenue declined 8.7% year on year to ¥2.893bn. Gross profit nevertheless increased to ¥1.776bn from ¥1.640bn in the prior-year period as cost of sales fell more sharply than revenue. The gross margin expanded by 960bp to 61.4%, indicating substantially improved unit economics or product mix. SG&A expense declined 9.4% to ¥2.430bn, slightly faster than the revenue decline. R&D expenditure was ¥673m, equivalent to 23.3% of revenue, maintaining a high investment level despite lower sales. The operating loss narrowed ¥434m year on year to ¥274m, with the operating margin improving by 138bp to negative 9.5%. This remains below the threshold for a self-sustaining operating model, and annualized revenue would be approximately ¥3.857bn if the nine-month run rate continued. Finance income of ¥789m, other income of ¥429m, and finance costs of ¥256m moved profit before tax to ¥368m despite the operating loss. Net income attributable to owners was ¥190m, compared with a ¥384m loss a year earlier, and basic EPS was ¥0.90. The 6.6% net margin is therefore not representative of underlying operating profitability because it depends on non-operating gains. Operating cash flow of ¥298m exceeded net income by 1.57x, providing support for reported earnings quality in cash terms. However, ¥342m of cash inflow from receivables was a material contributor to operating cash flow, while inventories increased by ¥122m. Reported free cash flow was ¥2.452bn, but this chiefly reflects a ¥2.154bn investing cash inflow from investment sales and maturities rather than internally generated operating cash. The balance sheet is exceptionally well capitalized, with an 81.2% equity ratio, ¥9.197bn of cash, and only ¥33m of interest-bearing borrowings. Near-term financial distress risk is therefore low, notwithstanding an operating loss. The principal forward implication is that valuation-sensitive finance and other income cannot substitute indefinitely for top-line growth and a positive operating margin. Investors should focus on whether gross-margin gains can be retained while revenue resumes growth and whether the elevated inventory cycle normalizes.
Profitability Analysis
The reported annualized DuPont ROE is 0.6%, decomposed into a 6.6% net profit margin, 0.079x asset turnover, and 1.23x financial leverage. Low asset turnover is the principal structural constraint on returns, reflecting a ¥49.003bn asset base relative to the FY2026 Q3 revenue run rate. Financial leverage is conservative and makes only a limited contribution to ROE, which is appropriate given the company's large equity base. The positive net margin masks a negative 9.5% EBIT margin: finance income and other income, rather than operations, converted a ¥274m operating loss into ¥190m of net income. Gross margin expanded from 51.8% to 61.4%, a 960bp improvement, while SG&A fell from ¥2.682bn to ¥2.430bn. The resulting operating-margin improvement to negative 9.5% from negative 22.3% was substantial, but operating leverage remains incomplete because revenue fell 8.7%. R&D was ¥673m, or 23.3% of revenue, underscoring that the company is retaining a growth-investment posture; this spending is strategically relevant but leaves the cost base high relative to current revenue. The quality alert for low operating efficiency is justified because EBIT remains negative and the company has not yet demonstrated recurring operating profitability. The ROIC quality alert, at negative 0.5%, likewise reflects negative operating earnings on a large invested asset base. The high-tax-burden alert is also material: the effective tax rate was 48.6%, leaving a tax burden of 0.516 versus a more normal level above 0.70. The high-interest-burden alert should be interpreted cautiously because the negative EBIT denominator makes the interest-burden ratio mathematically non-meaningful; nevertheless, finance costs of ¥256m exceeded the operating loss by 93%, reinforcing that positive pre-tax income was not generated from operations.
Growth Assessment
Revenue contraction of 8.7% to ¥2.893bn indicates that demand conversion remains the key operating issue. The sharp gross-margin expansion suggests progress in pricing, product mix, manufacturing efficiency, or cost control, but its durability requires stabilization in sales volume. SG&A declined 9.4%, demonstrating cost discipline and slightly favorable operating leverage relative to revenue. R&D spending declined only 4.1% year on year, preserving technology investment but limiting the extent to which the company can reduce fixed costs. The annualized FY2026 Q3 revenue run rate is approximately ¥3.857bn, and the annualized operating loss run rate is approximately ¥365m. High R&D intensity of 23.3% is well above typical manufacturing and electronics benchmarks and supports innovation investment, but it raises the revenue scale required to reach break-even. Net income improvement is not a reliable indicator of core growth because finance income and other income were larger than the operating loss. The company needs sustained revenue growth and continued gross-margin retention to convert the current gross-profit improvement into recurring operating earnings.
Financial Health
Financial health is strong from a liquidity and solvency perspective. Current assets were ¥16.725bn against implied current liabilities of ¥1.125bn, producing a calculated current ratio of approximately 14.9x and a substantial liquidity buffer. Cash and cash equivalents totaled ¥9.197bn, while current other financial assets were ¥5.818bn. Interest-bearing borrowings were only ¥33m, comprising ¥18m current and ¥15m non-current borrowings, compared with ¥39.795bn of total equity. The reported debt-to-equity ratio of 0.23x is conservative and well below the 2.0x risk threshold. Lease liabilities totaled ¥401m, and right-of-use assets were ¥376m; these obligations are manageable relative to liquid resources and equity. Non-current liabilities of ¥8.083bn are dominated by ¥2.424bn of deferred tax liabilities, alongside lease liabilities and ¥191m of provisions. There is no apparent short-term maturity mismatch because current liquid assets substantially exceed current obligations. Accounts receivable declined 42.6% year on year to ¥459m, which improved cash conversion and reduced receivables exposure, although it may also reflect lower revenue or collection timing. Retained earnings improved ¥190m to negative ¥611m as the company returned to profitability, but accumulated retained losses remain. Goodwill was ¥1.846bn, equal to only 4.6% of equity and 3.8% of assets, so balance-sheet dependence on acquired value and associated impairment risk are limited. PPE was ¥13.076bn, or 26.7% of total assets, while non-current financial assets were ¥15.839bn; asset productivity, rather than leverage, is the central balance-sheet consideration.
Notable B/S Changes
Accounts receivable: -¥341m (-42.6%) to ¥459m - supported operating cash flow through a ¥342m receivables release, while also reflecting lower revenue and/or collection timing. Retained earnings: +¥190m (+23.7%) to -¥611m - the FY2026 Q3 net profit reduced accumulated losses, although retained earnings remain negative. Cash and cash equivalents: +¥2.373bn (+34.8%) to ¥9.197bn - cash increased mainly alongside a ¥2.154bn investing cash inflow from financial-asset transactions. Other financial assets, current: -¥2.215bn (-27.6%) to ¥5.818bn - consistent with reallocation or monetization of financial assets during the period. Goodwill: +¥80m (+4.5%) to ¥1.846bn - modest increase; goodwill remains low at 4.6% of equity, limiting impairment sensitivity.
Cash Flow Quality
Cash-flow quality was favorable at the reported earnings level, with operating cash flow of ¥298m equal to 1.57x net income of ¥190m. The negative 0.2% accruals ratio also indicates that reported profit was not supported by aggressive accrual creation. Operating cash flow was aided materially by a ¥342m decrease in receivables and a ¥54m increase in payables. These favorable working-capital movements were partly offset by a ¥122m inventory build and ¥214m of other working-capital outflows. The receivables release is supportive in the current period but is not necessarily repeatable, so it should not be treated as a permanent source of cash generation. The inventory quality alert is material: annualized inventory days were 256 days, far above both the 90-day warning level and the 60-day manufacturing benchmark. The 156-day annualized cash conversion cycle is also elevated above the 120-day warning threshold, indicating that inventory ties up cash for a prolonged period despite low receivables. For a robotics and healthcare-equipment business, long lead times and project-based delivery can contribute to inventory duration, but a cycle of this length increases obsolescence, demand-forecast, and working-capital risks. Capital expenditure was only ¥12m, resulting in conventional operating cash flow less capital expenditure of ¥286m. Reported free cash flow of ¥2.452bn includes the ¥2.154bn net investing inflow, principally ¥17.984bn of investment-sale proceeds against ¥15.000bn of investment purchases and ¥783m of time-deposit placements. Accordingly, the reported free-cash-flow figure reflects active financial-asset reallocation and should not be interpreted as recurring operating free cash flow. Cash increased ¥2.373bn during the period to ¥9.197bn, strengthening already ample liquidity.
Dividend Sustainability
The company paid no Q2 dividend, so there is no current dividend cash commitment or payout ratio to assess. With annualized operating profitability still negative, retaining capital remains consistent with the underlying earnings profile despite positive reported net income. Conventional operating cash flow less capital expenditure was positive at ¥286m, but cash generation benefited from receivables collection and should be assessed over a longer period. The very strong liquidity position and low borrowing provide financial capacity, but the priority for internally generated cash is supporting R&D, inventory requirements, and the transition to recurring operating profitability. Any future dividend policy would be more sustainable once operating income, rather than non-operating income, consistently covers shareholder distributions.
Risk Assessment
Business risks include Revenue declined 8.7% year on year to ¥2.893bn, and the company remains dependent on rebuilding sales volume to absorb its R&D and SG&A base., The operating margin remained negative at 9.5%, despite a 960bp gross-margin improvement, leaving the business exposed if gross-margin gains reverse., Annualized inventory days of 256 and an annualized cash conversion cycle of 156 days create inventory obsolescence and demand-forecast risk; this is particularly relevant for technology-intensive robotics and medical/rehabilitation equipment with product-cycle and regulatory requirements., R&D spending of ¥673m, or 23.3% of revenue, supports innovation but raises execution risk if commercialization and revenue scaling lag investment., Goodwill of ¥1.846bn is modest relative to equity, limiting but not eliminating acquisition integration and impairment risk..
Financial risks include Pre-tax profitability depended on ¥789m of finance income and ¥429m of other income while operating income was negative ¥274m; volatility in investment returns or other income could quickly reverse reported net profitability., The effective tax rate was 48.6%, producing a tax burden of 0.516 and reducing conversion of pre-tax income into net income., The quality alert's negative interest-burden ratio reflects a loss-making EBIT base; finance costs of ¥256m remain sizable relative to operating earnings, even though absolute debt is low., A large share of assets is held in financial assets, including ¥5.818bn current and ¥15.839bn non-current other financial assets, exposing reported results and liquidity composition to investment-market movements..
Key concerns include Highest priority: establish recurring operating profitability through revenue growth and sustained gross-margin improvement., High priority: reduce the inventory cycle and cash conversion cycle without impairing product availability or customer delivery., High priority: assess the recurrence and composition of finance income and other income, as they currently underpin net profit., Moderate priority: monitor tax-rate normalization and its effect on earnings conversion., Moderate priority: improve annualized ROIC from negative 0.5% and annualized ROE from 0.6% through stronger asset utilization rather than additional leverage..
Investment Implications
Key takeaways include The operating loss narrowed by ¥434m year on year to ¥274m, driven by gross-margin expansion and SG&A reduction., Net income of ¥190m was supported by non-operating income, so it does not yet demonstrate a fully profitable core business., Operating cash flow exceeded net income, but receivables collection was a significant contributor and inventory increased., The balance sheet is highly resilient, with an 81.2% equity ratio, ¥9.197bn of cash, and minimal interest-bearing borrowings., Long annualized inventory days and a long annualized cash conversion cycle are the most prominent operating-capital concerns..
Metrics to watch include Revenue growth and the operating-margin path from negative 9.5% toward break-even, Gross-margin retention after the 960bp year-on-year expansion to 61.4%, R&D intensity and evidence that ¥673m of R&D expenditure translates into commercial revenue, Annualized inventory days of 256 and the annualized cash conversion cycle of 156 days, The mix, recurrence, and market sensitivity of finance income and other income, Effective tax rate, which was elevated at 48.6%, Annualized ROIC of negative 0.5% and annualized ROE of 0.6%.
Regarding relative positioning, CYBERDYNE is financially conservative relative to leveraged growth companies, with exceptional liquidity and negligible borrowing, but its operating profile remains weaker than a mature profitable medical-technology or manufacturing peer because revenue is contracting, operating margin is negative, asset turnover is low, and reported net income is dependent on non-operating gains.